相关实验视频
Updated: Jul 10, 2025

04:01
Transurethral Instillation Procedure in Adult Male Mouse
Published on: November 2, 2017
15.8K
氧化丁宁可以改善人类膀上皮细胞中LPS诱导的炎症反应
Cheng Chen1, Jiangtao Li2, Juan Wang3
1Department of Pharmacy, The First People's Hospital of Yibin, Yibin, China.
Journal of biochemical and molecular toxicology
|November 27, 2023
概括
氧化丁氨酸有效地减少了由脂多糖 (LPS) 刺激的膀上皮细胞中的炎症和氧化应激. 这项研究突出了Oxybutynin.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 尿路感染 (UTI) 是一种常见的细菌感染,影响全球数百万人.
- 尿道上皮细胞的损伤是尿路感染发展的关键初步步骤.
- 用于尿失禁的氧化丁宁显示出对膀组织的潜在保护作用.
研究的目的:
- 为了研究Oxybutynin对人类膀上皮细胞中脂聚糖 (LPS) 诱导的炎症的抗炎作用.
- 评估氧化丁宁对T24膀细胞中氧化应激标志物和炎症通路的影响.
主要方法:
- 人类膀T24细胞被单独用LPS (1μg/mL) 或用Oxybutynin (10和20μM) 治疗24小时.
- 氧化应激生物标志物 (ROS,8-OHdG,MDA) 和氧化的评估水平.
- 测量了炎症标志物,包括细胞因子,MMP-2,MMP-9,MCP-1和TLR4/NF-κB通路.
主要成果:
- 在T24细胞中,LPS挑战显著增加了氧化应激和氧化生产.
- 氧化丁宁治疗明显抑制了这些氧化应激标志物.
- 由LPS诱导的细胞因子,MMP和MCP-1的释放被Oxybutynin显著逆转.
- 氧化丁宁抑制了托尔类受体4 / 核因子-κB通路的激活.
结论:
- 氧化丁尼在LPS刺激的人类膀上皮细胞中表现出显著的抗炎和抗氧化特性.
- 该药物通过抑制关键炎症途径有效地减轻LPS诱导的细胞损伤.
- 这些发现表明,oxybutynin可能提供超出尿失禁的治疗益处,可能在管理尿路感染.
更多相关视频
06:36A Decentralized Ex Vivo Murine Bladder Model with the Detrusor Muscle Removed for Direct Access to the Suburothelium during Bladder Filling
Published on: November 28, 2019
7.2K
10:26Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
26.3K
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
179
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
179
Drugs for Treatment of Diarrhea-Predominant IBS
182
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
182